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Introduction: Twice daily (b.i.d.) inhalation of TOBI™ (300mg/5mL) in a 28-day
on/off-dosing regimen has previously proven its safety and efﬁcacy for the treatment
of Pseudomonas aeruginosa (P.a.) in CF subjects.
This randomized, open label, cross-over study explored the impact of of continuous
o.d. (1×300mg/d) and b.i.d. (2×300mg/d) treatment of TOBI™ via PARI eFlow™
rapid on pharmacokinetics (PK) after 4 and 8 wks in CF patients chronically infected
with P.a. The primary endpoint was serum PK of tobramycin (AUC0−90′ ). Further
objectives were safety, change in MIC of P.a. and lung function.
Results: 24 of 29 randomized patients completed both treatment regimens, mean
age was 19.8 (range: 8−35) yrs. For o.d. treatment, serum levels were 20% higher
after 8 wks compared with 4 wks (AUC0−90′ ratio: 1.203, 95% CI: 0.818–1.468)
whereas under b.i.d. treatment there was a 40% decrease after 8 wks compared to
4 wks (AUC0−90′ ratio: 0.608, 95% CI: 0.435–10.850). AUC0−90′ of o.d. and b.i.d.
after 8 wks did not differ signiﬁcantly.
Overall number of patients reporting an AE was similar among treatment groups:
o.d. N = 20 (76.9%) and b.i.d. N = 21 (75.0%). Most common AEs were
nasopharyngitis, headache and cough. Three SAEs have been reported (exacer-
bation, orthostatic dysregulation and aspergillosis), none was considered related to
treatment.
Conclusion: Results from this study indicate acceptable safety and tolerability of
continuous treatment with TOBI™ and justify exposure of larger populations to
alternative treatment regimens in future studies.
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Introduction: New inhaled antimicrobials for CF patients are needed due to
increased resistance, decreased efﬁcacy and poor compliance/tolerability. This study
assessed the efﬁcacy and safety of MP-376, a novel levoﬂoxacin formulation for
inhalation, in CF patients with extensive previous use of inhaled antibiotics.
Methods: Randomized, double-blind, placebo controlled trial of 3 dose groups
of MP-376 (120mg QD, 240mg QD, 240mg BID) vs. placebo for 28 days,
delivered by a customized investigational PARI eFlow nebulizer. Inclusion criteria:
age 16 years, chronic PA airways infection, FEV1 between 25−85% predicted,
and 3 courses of inhaled antibiotics over the past 12 months.
Results: 151 patients enrolled with mean baseline characteristics of age 29 years,
FEV1 52% of predicted, and 4.8 courses of inhaled antibiotics over last 12 months.
Concomitant respiratory medications included dornase-alpha (78%), azithromycin
(74%), and hypertonic saline (46%). Improvement in lung function was observed
in all dose groups, the largest seen with 240mg BID. At Day 28, improvements
over placebo in this group were change in FEV1 8.6% (p = 0.0026), relative change
in percent predicted FEV1 10.9% (p = 0.0008), change in FVC 5.7% (p = 0.0221)
and change in FEF 25−75 22.3% (p< 0.0001). Statistically signiﬁcant results were
also observed in all MP-376 dose groups for sputum PA density reduction and in
time to need for inhaled and/or systemic anti-PA antimicrobials.
Conclusion: Nebulized MP-376 (Aeroquin) demonstrated statistically and clini-
cally signiﬁcant improvement in lung function in this heavily-treated CF patient
population with PA lung infection. Phase 3 studies are planned.
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Objective: MP-376 is a novel inhaled formulation of levoﬂoxacin. We compared
the safety, tolerability, and PK proﬁle of MP-376 (50 and 100mg/mL) at 2 dose
levels in stable CF patients.
Methods: We enrolled 10 CF patients 16 yrs old who received in random order
and separated by a 7-day washout period a single 180mg dose of each formulation.
After an additional 7-day wash-out, patients received 7 consecutive days of 240mg
QD (100mg/ml). MP-376 was delivered with an investigational eFlow nebulizer.
Serum and sputum levoﬂoxacin levels were obtained at intervals over 24 hours after
each 180mg dose and after the last 240mg dose.
Results: The mean sputum levoﬂoxacin PK values with the 180mg dose delivered
as 50 vs 100mg/ml were: Cmax 2,563 vs. 2,932mg/L; AUC 1,891 vs 1,961mg·h/L
respectively. Corresponding serum Cmax values were: 0.95 vs 1.28mg/L and AUC
8.1 vs 9.8mg·h/L (not statistically signiﬁcant). After 7-days of 240mg QD dosing,
the sputum Cmax was 4,691mg/L and AUC was 4,571mg·h/L. The serum Cmax
and AUC increased proportionally with dose. Delivery time was shorter with the
higher concentration, and was 4−6 minutes for the 240mg dose. MP-376 was safe
and well tolerated at both doses and concentrations.
Conclusions: MP-376 provides high sputum levoﬂoxacin concentrations resulting
in high PK-PD indices for CF pathogens, and low serum exposures. MP-376
(100mg/ml) enables delivery of 240mg doses in 4−6 minutes and is being advanced
into Phase 3 clinical trials.
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Introduction: The upper airways are regularly affected in CF and rhinosinusitis
relevantly impairs patients’ quality of life and overall health. In general the sinonasal
compartment is not reached by conventional inhalatory therapy but the new Pari
Sinus device was shown to deliver aerosol into paranasal spaces by scintigraﬁc
studies in humans. Previously, we presented preliminary data from 5 CF-patients
included in our DBPC pilot-study on sinonasal inhalation of dornase alfa with the
device.
Methods: Now we present the results from the consecutive principal study including
23 CF patients (11f, mean age 21.7 yrs) randomised to inhale either dornase alfa
or 0.9% NaCl for 28 days and, after a wash-out period of 28 days, crossed over
to the alternative treatment. Primary outcome parameters assessed was the Sino-
Nasal-Outcome-Test (SNOT-20) a disease-speciﬁc quality of life tool.
Results: Whereas normal saline was not associated with relevant changes in
SNOT-20 scores, dornase alfa improved quality of life (p = 0.005). Primary nasal
parameters “obstruction”, “sneezing or running nose”, “mucopurulent secretions”,
“reduced sense of smelling”, and “facial pain” improved with verum (p = 0.003) but
not with isotonic saline. Also FEV1 increased signiﬁcantly with verum (p = 0.024).
Sinonasal inhalation regularly was well tolerated except in two patients who suffered
from self-limiting epistaxis.
Conclusion: Even in the short period of 4 weeks of treatment the new method
of sinonasal inhalation of dornase alfa led to signiﬁcant reduction of sinonasal
symptoms in CF-patients.
